L
Luca Bianchi
Researcher at University of Rome Tor Vergata
Publications - 371
Citations - 5286
Luca Bianchi is an academic researcher from University of Rome Tor Vergata. The author has contributed to research in topics: Psoriasis & Psoriatic arthritis. The author has an hindex of 29, co-authored 367 publications receiving 3630 citations. Previous affiliations of Luca Bianchi include Sapienza University of Rome & Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.
Papers
More filters
Journal ArticleDOI
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis.
Paolo Gisondi,Gianfranco Altomare,Fabio Ayala,Federico Bardazzi,Luca Bianchi,Andrea Chiricozzi,Antonio Costanzo,Andrea Conti,Paolo Dapavo,C. De Simone,Caterina Foti,Luigi Naldi,A. Offidani,Andrea Parodi,Stefano Piaserico,Francesca Prignano,Franco Rongioletti,Luca Stingeni,Marina Talamonti,Giampiero Girolomoni +19 more
TL;DR: Recommendations on the treatment of psoriasis in special patient populations were agreed and the use, screening and monitoring of systemic therapies were based on the 2015 S3 European Dermatology Forum/European Academy of Dermatologists and Venereology psorosis guidelines.
Journal ArticleDOI
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
Marina Papoutsaki,Maria Sole Chimenti,Antonio Costanzo,Marina Talamonti,Arianna Zangrilli,Alessandro Giunta,Luca Bianchi,Sergio Chimenti +7 more
TL;DR: Monotherapy with adalimumab 40 mg weekly proved to be an effective and safe treatment for the management of plaque-type psoriasis and psoriatic arthritis, with a rapid onset of action in patients whose disease had been refractory to both conventional and biologic agents.
Journal ArticleDOI
Potential of Curcumin in Skin Disorders
Laura Vollono,Mattia Falconi,Roberta Gaziano,Federico Iacovelli,Emi Dika,Chiara Terracciano,Luca Bianchi,Elena Campione +7 more
TL;DR: The results suggest that curcumin may represent a low-cost, well-tolerated, effective agent in the treatment of skin diseases, and bypass of limitations of its in vivo use (low oral bioavailability, metabolism) is essential in order to conduct larger clinical trials that could confirm these observations.
Journal ArticleDOI
Lactoferrin as Protective Natural Barrier of Respiratory and Intestinal Mucosa against Coronavirus Infection and Inflammation.
Elena Campione,Terenzio Cosio,Luigi Rosa,Caterina Lanna,Stefano Di Girolamo,Roberta Gaziano,Piera Valenti,Luca Bianchi +7 more
TL;DR: Lactoferrin could counteract the coronavirus infection and inflammation, acting either as natural barrier of both respiratory and intestinal mucosa or reverting the iron disorders related to the viral colonization.
Journal ArticleDOI
CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis.
Roberto Lande,Ernest Y. Lee,Raffaella Palazzo,Barbara Marinari,Immacolata Pietraforte,Giancarlo Santiago Santos,Yves Benoît Mattenberger,Francesca Spadaro,Katia Stefanantoni,Nicoletta Iannace,Aleksandra Maria Dufour,Mario Falchi,Manuela Bianco,Elisabetta Botti,Luca Bianchi,Montserrat Alvarez,Valeria Riccieri,Marie-Elise Truchetet,Gerard C. L. Wong,Carlo Chizzolini,Loredana Frasca +20 more
TL;DR: A direct link between CXCL4 overexpression and the IFN-I-gene signature in SSc is established and a paradigm in which chemokines can drastically modulate innate immune receptors without being direct agonists is outlined.